Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates

Overview

Journal Front Neurol

Specialty Neurology

Date 2019 Aug 21

PMID 31428042

Citations 21

Authors

Flore Gouel

Anne-Sophie Rolland

Jean-Christophe Devedjian

Thierry Burnouf

David Devos

Affiliations

Soon will be listed here.

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that typically results in death within 3-5 years after diagnosis. To date, there is no curative treatment and therefore an urgent unmet need of neuroprotective and/or neurorestorative treatments. Due to their spectrum of capacities in the central nervous system-e.g., development, plasticity, maintenance, neurogenesis-neurotrophic growth factors (NTF) have been exploited for therapeutic strategies in ALS for decades. In this review we present the initial strategy of using single NTF by different routes of administration to the use of stem cells transplantation to express a multiple NTFs-rich secretome to finally focus on a new biotherapy based on the human platelet lysates, the natural healing system containing a mix of pleitropic NTF and having immunomodulatory function. This review highlights that this latter treatment may be crucial to power the neuroprotection and/or neurorestoration therapy requested in this devastating disease.

Citing Articles

Proteomics of human platelet lysates and insight from animal studies on platelet protein diffusion to hippocampus upon intranasal administration.

Le N, Han C, Delila L, Nebie O, Chien H, Wu Y APL Bioeng. 2024; 8(2):026111.

PMID: 38726021 PMC: 11080963. DOI: 10.1063/5.0196553.

Whole-Body Cryostimulation in Multiple Sclerosis: A Scoping Review.

Alito A, Fontana J, Franzini Tibaldeo E, Verme F, Pitera P, Miller E J Clin Med. 2024; 13(7).

PMID: 38610768 PMC: 11012586. DOI: 10.3390/jcm13072003.

Mesenchymal stem cell therapy in amyotrophic lateral sclerosis (ALS) patients: A comprehensive review of disease information and future perspectives.

Najafi S, Najafi P, Farkhad N, Hosseini Torshizi G, Assaran Darban R, Boroumand A Iran J Basic Med Sci. 2023; 26(8):872-881.

PMID: 37427325 PMC: 10329242. DOI: 10.22038/IJBMS.2023.66364.14572.

Neural Differentiation of Induced Pluripotent Stem Cells for a Xenogeneic Material-Free 3D Neurological Disease Model Neurulation from Pluripotent Cells Using a Human Hydrogel.

Valerio L, Carrick F, Bedoya L, Sreerama S, Sugaya K Curr Issues Mol Biol. 2023; 45(6):4574-4588.

PMID: 37367039 PMC: 10297326. DOI: 10.3390/cimb45060290.

Neuroprotective activity of a virus-safe nanofiltered human platelet lysate depleted of extracellular vesicles in Parkinson's disease and traumatic brain injury models.

Delila L, Nebie O, Le N, Barro L, Chou M, Wu Y Bioeng Transl Med. 2023; 8(1):e10360.

PMID: 36684076 PMC: 9842020. DOI: 10.1002/btm2.10360.

References

Boonman Z, Isacson O . Apoptosis in neuronal development and transplantation: role of caspases and trophic factors. Exp Neurol. 1999; 156(1):1-15. DOI: 10.1006/exnr.1999.7056. View

. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology. 1999; 52(7):1427-33. DOI: 10.1212/wnl.52.7.1427. View

Ende N, Weinstein F, Chen R, Ende M . Human umbilical cord blood effect on sod mice (amyotrophic lateral sclerosis). Life Sci. 2000; 67(1):53-9. DOI: 10.1016/s0024-3205(00)00602-0. View

Chen R, Ende N . The potential for the use of mononuclear cells from human umbilical cord blood in the treatment of amyotrophic lateral sclerosis in SOD1 mice. J Med. 2000; 31(1-2):21-30. View

Ochs G, Penn R, York M, Giess R, Beck M, Tonn J . A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 1(3):201-6. DOI: 10.1080/14660820050515197. View

Wang L, Lu Y, Muramatsu S, Ikeguchi K, Fujimoto K, Okada T . Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci. 2002; 22(16):6920-8. PMC: 6757879. DOI: 20026668. View

Kalra S, Genge A, Arnold D . A prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003; 4(1):22-6. DOI: 10.1080/14660820310006689. View

Garbuzova-Davis S, Willing A, Zigova T, Saporta S, Justen E, Lane J . Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation. J Hematother Stem Cell Res. 2003; 12(3):255-70. DOI: 10.1089/152581603322022990. View

Kaspar B, Llado J, Sherkat N, Rothstein J, Gage F . Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003; 301(5634):839-42. DOI: 10.1126/science.1086137. View

10.

Turner B, Cheah I, Macfarlane K, Lopes E, Petratos S, Langford S . Antisense peptide nucleic acid-mediated knockdown of the p75 neurotrophin receptor delays motor neuron disease in mutant SOD1 transgenic mice. J Neurochem. 2003; 87(3):752-63. DOI: 10.1046/j.1471-4159.2003.02053.x. View

11.

Zheng C, Nennesmo I, Fadeel B, Henter J . Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Ann Neurol. 2004; 56(4):564-7. DOI: 10.1002/ana.20223. View

12.

Storkebaum E, Lambrechts D, Dewerchin M, Moreno-Murciano M, Appelmans S, Oh H . Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci. 2004; 8(1):85-92. DOI: 10.1038/nn1360. View

13.

Klein S, Behrstock S, McHugh J, Hoffmann K, Wallace K, Suzuki M . GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum Gene Ther. 2005; 16(4):509-21. DOI: 10.1089/hum.2005.16.509. View

14.

Beck M, Flachenecker P, Magnus T, Giess R, Reiners K, Toyka K . Autonomic dysfunction in ALS: a preliminary study on the effects of intrathecal BDNF. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005; 6(2):100-3. DOI: 10.1080/14660820510028412. View

15.

Nagano I, Shiote M, Murakami T, Kamada H, Hamakawa Y, Matsubara E . Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol Res. 2005; 27(7):768-72. DOI: 10.1179/016164105X39860. View

16.

Sendtner M, Schmalbruch H, Stockli K, Carroll P, Kreutzberg G, Thoenen H . Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature. 1992; 358(6386):502-4. DOI: 10.1038/358502a0. View

17.

Kotzbauer P, Holtzman D . Expectations and challenges in the therapeutic use of neurotrophic factors. Ann Neurol. 2006; 59(3):444-7. DOI: 10.1002/ana.20794. View

18.

Xu L, Yan J, Chen D, Welsh A, Hazel T, Johe K . Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation. 2006; 82(7):865-75. DOI: 10.1097/01.tp.0000235532.00920.7a. View

19.

Habisch H, Janowski M, Binder D, Kuzma-Kozakiewicz M, Widmann A, Habich A . Intrathecal application of neuroectodermally converted stem cells into a mouse model of ALS: limited intraparenchymal migration and survival narrows therapeutic effects. J Neural Transm (Vienna). 2007; 114(11):1395-406. DOI: 10.1007/s00702-007-0748-y. View

20.

Suzuki M, McHugh J, Tork C, Shelley B, Klein S, Aebischer P . GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One. 2007; 2(8):e689. PMC: 1925150. DOI: 10.1371/journal.pone.0000689. View